Key result
SAPIEN 3 THV evaluated for five-year safety and effectiveness in RVOT dysfunction.
Why the study?
The COMPASSION S3 trial was designed to evaluate the safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve for TPVR in patients with a dysfunctional RVOT conduit or previously implanted valve in the pulmonic position.
Does the SAPIEN 3 Transcatheter Heart Valve provide safety and effectiveness for transcatheter pulmonic valve replacement in patients with a dysfunctional right ventricular outflow tract conduit or previously implanted valve?
Does the SAPIEN 3 Transcatheter Heart Valve provide safety and effectiveness for transcatheter pulmonic valve replacement in patients with a dysfunctional right ventricular outflow tract conduit or previously implanted valve?
Answers are grounded in this paper and cite their sources.
The COMPASSION S3 trial was designed to evaluate the safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve (S3 THV) for transcatheter pulmonic valve replacement (TPVR) in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position. One-year outcomes from the main cohort have been previously published.
No takes yet. Share an insight, caveat, or question.
Hainstock et al. (2026) studied this question. The SAPIEN 3 Transcatheter Heart Valve was evaluated for five-year safety and effectiveness in treating patients with right ventricular outflow tract dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: